JP2010529197A - 酸化的ストレス関連疾患の治療および診断のための材料および方法 - Google Patents

酸化的ストレス関連疾患の治療および診断のための材料および方法 Download PDF

Info

Publication number
JP2010529197A
JP2010529197A JP2010512198A JP2010512198A JP2010529197A JP 2010529197 A JP2010529197 A JP 2010529197A JP 2010512198 A JP2010512198 A JP 2010512198A JP 2010512198 A JP2010512198 A JP 2010512198A JP 2010529197 A JP2010529197 A JP 2010529197A
Authority
JP
Japan
Prior art keywords
composition
acid
ulcerative colitis
hydrogen peroxide
once
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2010512198A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010529197A5 (enExample
Inventor
ジェイ プラーヴダ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2010529197A publication Critical patent/JP2010529197A/ja
Publication of JP2010529197A5 publication Critical patent/JP2010529197A5/ja
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Dental Preparations (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2010512198A 2007-06-13 2008-06-13 酸化的ストレス関連疾患の治療および診断のための材料および方法 Abandoned JP2010529197A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93450507P 2007-06-13 2007-06-13
US6374508P 2008-02-06 2008-02-06
PCT/US2008/007401 WO2008156671A2 (en) 2007-06-13 2008-06-13 Materials and methods for treatment and diagnosis of disorders associated with oxidative stress

Publications (2)

Publication Number Publication Date
JP2010529197A true JP2010529197A (ja) 2010-08-26
JP2010529197A5 JP2010529197A5 (enExample) 2012-08-09

Family

ID=40156844

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010512198A Abandoned JP2010529197A (ja) 2007-06-13 2008-06-13 酸化的ストレス関連疾患の治療および診断のための材料および方法

Country Status (14)

Country Link
US (2) US8476233B2 (enExample)
EP (2) EP2162125B1 (enExample)
JP (1) JP2010529197A (enExample)
KR (1) KR20100038098A (enExample)
CN (1) CN101707877B (enExample)
AT (1) ATE529105T1 (enExample)
AU (1) AU2008266996A1 (enExample)
BR (1) BRPI0812729A2 (enExample)
CA (1) CA2691132C (enExample)
IL (1) IL202685A0 (enExample)
MX (1) MX2009013683A (enExample)
NZ (1) NZ581710A (enExample)
WO (1) WO2008156671A2 (enExample)
ZA (1) ZA200908828B (enExample)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015506999A (ja) * 2012-02-13 2015-03-05 コスモ・テクノロジーズ・リミテツド 少なくとも１つの炎症性要素を呈する腸管疾患を治療するための方法
JP2015509539A (ja) * 2012-03-07 2015-03-30 サンタラス， インコーポレイテッドＳａｎｔａｒｕｓ，Ｉｎｃ． メラサミンの放出制御固形製剤
JP2015536995A (ja) * 2012-11-09 2015-12-24 サイドース・エルエルシー 潰瘍性大腸炎の治療のための長期安定性を有する浣腸剤組成物
JP2018519345A (ja) * 2015-07-08 2018-07-19 ドクトル ファルク ファルマ ゲーエムベーハー 直腸の炎症性変化の治療用医薬製剤
JP2018535276A (ja) * 2015-11-27 2018-11-29 ビルベヘール・ベー・フェー 炎症性疾患に使用するための酪酸塩
JP2019113375A (ja) * 2017-12-22 2019-07-11 サッポロホールディングス株式会社 腸内環境評価方法、大腸炎罹患リスク評価方法、及び腸内環境改善物質のスクリーニング方法
JP2019530477A (ja) * 2016-09-26 2019-10-24 プレシジョン・メディスン・ホールディングス・プロプライエタリー・リミテッド 精神分裂病および分裂情動性精神病の診断、予後、および処置
JP2022533635A (ja) * 2019-05-16 2022-07-25 イントラクト、ファーマ、リミテッド 安定剤としてジペプチドを含むタンパク質組成物
WO2025079348A1 (ja) * 2023-10-11 2025-04-17 国立大学法人東北大学 炎症性疾患の治療薬、及び治療薬のスクリーニング方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916546B2 (en) 2003-08-29 2014-12-23 Therapeutic Research Llc Materials and methods for treatment and diagnosis of disorders associated with oxidative stress
US20100112088A1 (en) * 2003-08-29 2010-05-06 Jay Pravda Materials and methods for treatment of disorders associated with oxidative stress
WO2014008273A2 (en) * 2012-07-03 2014-01-09 Jay Pravda Methods for treating, diagnosing and/or monitoring progression of oxo associated states
CN103622974B (zh) * 2013-12-05 2016-04-20 武汉武药科技有限公司 一种含美沙拉嗪和n-乙酰半胱氨酸的复方栓剂及其制备方法
EA201791686A8 (ru) 2015-01-26 2018-10-31 Др. Фальк Фарма Гмбх Клизма для ректального введения
WO2018122086A1 (en) * 2016-12-28 2018-07-05 Dr. Falk Pharma Gmbh Enema for rectal application
CN108034631A (zh) * 2017-12-04 2018-05-15 武汉轻工大学 一种双氧水诱导猪小肠上皮细胞凋亡模型的建立方法
EP3741368B1 (en) * 2018-01-18 2024-03-06 Keio University Capsule for use in treating ulcerative colitis
WO2024026200A1 (en) * 2022-07-27 2024-02-01 Redox Bioscience LLC Methods and compounds for treating ulcerative colitis, systemic lupus erythematosus, sepsis, and post-sepsis syndrome

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211777A (en) * 1977-11-25 1980-07-08 Fisons Limited Compositions comprising a compound having sodium cromoglycate activity and aminosalicylic acid
WO1981002671A1 (en) 1980-03-20 1981-10-01 Ferring Farma Lab Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration
US4657900A (en) * 1983-09-27 1987-04-14 Rowell Laboratories Pharmaceutical article of manufacture comprising a bisulfite stabilized aqueous solution of 5-aminosalicylic acid and method
EP0382066A3 (de) 1989-02-09 1992-01-08 ASTA Medica Aktiengesellschaft Verwendung von Dihydroliponsäure als Analgetikum, Antiphlogistikum und/oder Zytoprotektivum
GB8909559D0 (en) * 1989-04-26 1989-06-14 Smith Kline French Lab Pharmaceutical compositions
US5378470A (en) 1989-07-25 1995-01-03 Henning Berlin Gmbh Rectally administered pharmaceutical preparation
JPH03169813A (ja) 1989-11-09 1991-07-23 Asta Pharma Ag 細胞保護作用を有する疼痛及び炎症性疾患及び／又はレトロウイルスに起因する病気の治療用医薬並びにその製法
DE4218572A1 (de) 1992-06-05 1993-12-09 Asta Medica Ag Synergistische Kombination von Arzneimitteln enthaltend als Wirkstoff alpha-Liponsäure, Dihydroliponsäure, deren Metaboliten sowie die oxidierten und reduzierten Enantiomere der alpha-Liponsäure wie die R-alpha-Liponsäure oder S-alpha-Liponsäure sowie Metaboliten der alpha-Liponsäure mit den Vitaminen A, B1-6, B12, C und E
US5569670A (en) 1992-06-05 1996-10-29 Asta Medica Aktiengesellschaft Combination medications containing alpha-lipoic acid and related
US20050090553A1 (en) 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
US6444221B1 (en) 1992-06-30 2002-09-03 Howard K. Shapiro Methods of treating chronic inflammatory diseases using carbonyl trapping agents
US8178516B2 (en) 1992-06-30 2012-05-15 Sylvan Labs, LLC Compositions and method for treatment of chronic inflammatory diseases
JP2917799B2 (ja) * 1994-03-11 1999-07-12 田辺製薬株式会社 消化管内適所放出型製剤
US5563131A (en) 1994-08-04 1996-10-08 Pherin Corporation Pregnane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
DE19509806A1 (de) 1995-03-21 1996-09-26 Basf Ag Lagerstabile Arzneiformen
US5817630A (en) 1997-03-18 1998-10-06 Austin Nutriceutical Corporation Glutathione antioxidant eye drops
US6197749B1 (en) 1997-10-29 2001-03-06 Ajinomoto Co., Inc. Method of suppressing immune responses by reducing intracellular content of glutathione in macrophages and monocytes
WO1999055326A1 (en) 1998-04-30 1999-11-04 Vit-Immune, L.C. Method of treatment of glutathione deficient mammals
CA2274943A1 (en) * 1998-06-17 1999-12-17 Stephen L. Wolman Compositions for the treatment and prevention of inflammatory diseases of the gastrointestinal tract and methods and uses thereof
AR042572A1 (es) 1999-04-02 2005-06-29 Sod Conseils Rech Applic Derivados de acido lipoico, procedimiento para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y utilizacion de dichos derivados para la preparacion de los referidos medicamentos
US6664287B2 (en) 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
EP1172110A3 (de) 2000-07-07 2003-09-17 Basf Aktiengesellschaft Verwendung von Liponsäure zur Verbesserung der Bioverfügbarkeit von Mineralsalzen
AU2002256507A1 (en) * 2001-05-09 2002-11-18 Novartis Ag Methods for selective immunomodulation using pimecrolimus
US20030235571A1 (en) 2002-06-19 2003-12-25 Gabriel Gojon-Romanillos Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
WO2004024868A2 (en) 2002-09-10 2004-03-25 National Jewish Medical And Research Center Product and process for liquefaction of mucus or sputum
US7157444B2 (en) 2002-12-21 2007-01-02 Deanna Jean Nelson Aminosalicylate derivatives for treatment of inflammatory bowel disease
DE10305661A1 (de) 2003-02-12 2004-08-26 Degussa Ag Darreichungsform zur Kolon-spezifischen Wirkstofffreisetzung
EP1603556A2 (en) * 2003-03-06 2005-12-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Sod mimic multifunctional compounds for treating inflammatory bowel disease
US20100112088A1 (en) 2003-08-29 2010-05-06 Jay Pravda Materials and methods for treatment of disorders associated with oxidative stress

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015506999A (ja) * 2012-02-13 2015-03-05 コスモ・テクノロジーズ・リミテツド 少なくとも１つの炎症性要素を呈する腸管疾患を治療するための方法
JP2017210476A (ja) * 2012-02-13 2017-11-30 コスモ・テクノロジーズ・リミテツド 少なくとも１つの炎症性要素を呈する腸管疾患を治療するための方法
JP2015509539A (ja) * 2012-03-07 2015-03-30 サンタラス， インコーポレイテッドＳａｎｔａｒｕｓ，Ｉｎｃ． メラサミンの放出制御固形製剤
JP2015536995A (ja) * 2012-11-09 2015-12-24 サイドース・エルエルシー 潰瘍性大腸炎の治療のための長期安定性を有する浣腸剤組成物
JP2018519345A (ja) * 2015-07-08 2018-07-19 ドクトル ファルク ファルマ ゲーエムベーハー 直腸の炎症性変化の治療用医薬製剤
JP2018535276A (ja) * 2015-11-27 2018-11-29 ビルベヘール・ベー・フェー 炎症性疾患に使用するための酪酸塩
JP2019530477A (ja) * 2016-09-26 2019-10-24 プレシジョン・メディスン・ホールディングス・プロプライエタリー・リミテッド 精神分裂病および分裂情動性精神病の診断、予後、および処置
JP2019113375A (ja) * 2017-12-22 2019-07-11 サッポロホールディングス株式会社 腸内環境評価方法、大腸炎罹患リスク評価方法、及び腸内環境改善物質のスクリーニング方法
JP2022533635A (ja) * 2019-05-16 2022-07-25 イントラクト、ファーマ、リミテッド 安定剤としてジペプチドを含むタンパク質組成物
JP7696831B2 (ja) 2019-05-16 2025-06-23 イントラクト、ファーマ、リミテッド 安定剤としてジペプチドを含むタンパク質組成物
WO2025079348A1 (ja) * 2023-10-11 2025-04-17 国立大学法人東北大学 炎症性疾患の治療薬、及び治療薬のスクリーニング方法

Also Published As

Publication number Publication date
EP2162125B1 (en) 2011-10-19
US20130344184A1 (en) 2013-12-26
ZA200908828B (en) 2010-12-29
BRPI0812729A2 (pt) 2019-02-12
WO2008156671A3 (en) 2009-03-12
US20100184728A1 (en) 2010-07-22
WO2008156671A2 (en) 2008-12-24
MX2009013683A (es) 2010-04-07
NZ581710A (en) 2012-02-24
CA2691132A1 (en) 2008-12-24
EP2392321A1 (en) 2011-12-07
CN101707877B (zh) 2013-01-09
CA2691132C (en) 2016-01-12
IL202685A0 (en) 2010-06-30
AU2008266996A1 (en) 2008-12-24
ATE529105T1 (de) 2011-11-15
EP2162125A2 (en) 2010-03-17
US8476233B2 (en) 2013-07-02
CN101707877A (zh) 2010-05-12
KR20100038098A (ko) 2010-04-12
EP2162125A4 (en) 2010-08-25

Similar Documents

Publication Publication Date Title
JP2010529197A (ja) 酸化的ストレス関連疾患の治療および診断のための材料および方法
JP2010529197A5 (enExample)
US7312243B1 (en) Materials and methods for treatment of gastrointestinal disorders
US20120322773A1 (en) Materials and methods for treatment of disorders associated with oxidative stress
Kang et al. Zinc prevention and treatment of alcoholic liver disease
Pravda Radical induction theory of ulcerative colitis
Sturniolo et al. Effect of zinc supplementation on intestinal permeability in experimental colitis
Cryer Mucosal defense and repair: role of prostaglandins in the stomach and duodenum
Ozturk et al. Anti-inflammatory effects of nesfatin-1 in rats with acetic acid-induced colitis and underlying mechanisms
JP5699396B2 (ja) 子宮内膜症の治療のためのｎ−アセチル−ｌ−システイン
Rastmanesh Potential of melatonin to treat or prevent age-related macular degeneration through stimulation of telomerase activity
Younis et al. Silymarin preconditioning protected insulin resistant rats from liver ischemia-reperfusion injury: role of endogenous H2S
KR20090015986A (ko) 위에서 아세트알데하이드를 결합시키기 위한 조성물 및 방법
KR20230023642A (ko) 간 장애의 조합 치료
US8785423B2 (en) Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseases
Shahid et al. Acinar cell production of leukotriene B4 contributes to development of neurogenic pancreatitis in mice
US10064877B2 (en) Materials and methods for treatment and diagnosis of disorders associated with oxidative stress
Kakimoto et al. Significance of chymase-dependent matrix metalloproteinase-9 activation on indomethacin-induced small intestinal damages in rats
Oliveira N-Acetylcysteine (nac): impacts on human health
Bours et al. Effects of oral adenosine 5'-triphosphate and adenosine in enteric-coated capsules on indomethacin-induced permeability changes in the human small intestine: a randomized cross-over study
JP2017527595A (ja) アルコールフラッシング反応およびアルコール誘発性過敏反応の治療および予防用製剤
US20240156832A1 (en) Methods of metabolizing metopimazine and its salts
Dugbartey Hydrogen Sulfide for the Treatment of Hypertensive Nephropathy and Calcium-Based Nephrolithiasis
CN116115550A (zh) 一种皮质类固醇的药物组合物及其制备方法
PT103420A (pt) Utilização do processo de indução da síntese de novo da glicoproteína p (gp - p) no tratamento das intoxicações dos mamíferos por xenobióticos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110613

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120612

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20120914